Sorry, you need to enable JavaScript to visit this website.

    UK Body Recommends Pfizer's Champix (varenicline) for Smokers

    Smokers in the UK Should Now Have Access to Champix

    (BUSINESS WIRE)--Pfizer Inc announced today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has recommended Champix (varenicline) for use on the National Health Service for adult smokers who have expressed a desire to quit. This gives smokers across England, Wales and Northern Ireland access to another important treatment option to help them quit smoking.

    In its Final Appraisal Determination, NICE concluded that varenicline was superior to NRT [nicotine replacement therapy] and bupropion in achieving continuous abstinence and that its use in smoking cessation was likely to be a cost-effective use of National Health Service resources.

    This guidance means that smokers who are serious about stopping have another choice from a good range of clinically proven treatments, said Professor Robert West, Professor of Health Psychology at University College London. Smokers who combine treatments with the right support for instance from smoking cessation services - could significantly increase their odds of successfully quitting for life.

    Champix is the first new prescription aid to smoking cessation treatment in nearly a decade. Pfizer discovered and developed Champix specifically as an aid to smoking cessation through its unique mechanism of action targeting the specific receptor to which nicotine binds. Champix is believed to work by reducing the severity of the smokers urge to smoke.

    This guidance in the U.K. recognizes the efficacy and cost-effectiveness of Champix, and encourages physicians and smokers to consider this treatment as a new treatment option to help smokers quit smoking, said Jack Watters, MD, Pfizers Vice President of International Medical Affairs. The implications of this ruling are particularly timely as they come just before World No Tobacco Day, when organizations and governments around the world will work to implement smoke-free policies, which may further encourage smokers to make a quit attempt.

    Smoking, the leading cause of preventable death worldwide, is responsible for five million deaths worldwide each year. By 2010, the World Health Organization estimates the annual global cost of tobacco-related illness to be approximately US$500 billion.

    The medication, varenicline, with trade name Chantix (varenicline) in the United States, received U.S. Food and Drug Administration approval as an aid to smoking cessation in May 2006. In the European Union, Champix received marketing authorization in September 2006 for use as a smoking cessation aid. For a patient prescribed Champix or Chantix, Pfizer also offers behavioral support, a personalized online interactive program to help smokers quit, at no extra cost. In clinical trials, varenicline was generally well tolerated with overall discontinuation rates similar to placebo. The most frequent side effects included nausea, headache, trouble sleeping and changes in dreaming.

    US patients and health care providers can visit or call 1-877-CHANTIX and register to receive more information about Chantix. For prescribing information, please visit

    Pfizer Inc
    Jack Cox, (212) 733-5017
    Oliver Stohlmann, +43 1 52115 337


    Sign up for the latest Pfizer Wire news alerts

    Receive real-time updates on Pfizer’s news delivered directly to your inbox.

    Our Pipeline: Potential Breakthroughs in the Making

    We're elevating our breakthroughs in a bold new way. Check out our new visualized product pipeline.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Media Asset Library

    Click here to view our media asset library.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.

    Stay up to date on the latest news and alerts through the Pfizer Wire

    Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox. 


    Sign Up Now